Kite Pharma Inc. (NASDAQ:KITE) shares were down 1.1% during mid-day trading on Tuesday . The stock traded as low as $60.30 and last traded at $60.58, with a volume of 200,551 shares traded. The stock had previously closed at $61.23.

Several analysts have recently weighed in on the stock. FBR & Co lowered shares of Kite Pharma to a “buy” rating in a research note on Tuesday, May 10th. Maxim Group reiterated a “buy” rating and issued a $87.00 price objective on shares of Kite Pharma in a research note on Tuesday, May 10th. Mizuho reiterated a “buy” rating and issued a $80.00 price objective (down previously from $90.00) on shares of Kite Pharma in a research note on Tuesday, May 10th. Canaccord Genuity reiterated a “buy” rating on shares of Kite Pharma in a research note on Tuesday, May 10th. Finally, Jefferies Group reiterated a “buy” rating on shares of Kite Pharma in a research note on Monday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the stock. Kite Pharma presently has a consensus rating of “Buy” and a consensus target price of $73.53.

The stock has a 50-day moving average price of $54.71 and a 200-day moving average price of $49.84. The stock’s market cap is $2.99 billion.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.30. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.86 million. During the same period last year, the business earned ($0.26) earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. On average, analysts anticipate that Kite Pharma Inc. will post ($5.83) earnings per share for the current fiscal year.

In other Kite Pharma news, SVP Jeffrey Wiezorek sold 1,500 shares of the firm’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $50.00, for a total value of $75,000.00. Following the transaction, the senior vice president now directly owns 16,367 shares of the company’s stock, valued at $818,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roy Doumani sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $57.91, for a total value of $579,100.00. Following the completion of the transaction, the director now directly owns 136,017 shares in the company, valued at $7,876,744.47. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in KITE. Dimensional Fund Advisors LP purchased a new position in shares of Kite Pharma during the fourth quarter valued at about $2,088,000. California Public Employees Retirement System boosted its position in shares of Kite Pharma by 58.8% in the fourth quarter. California Public Employees Retirement System now owns 51,300 shares of the biopharmaceutical company’s stock valued at $3,161,000 after buying an additional 19,000 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its position in shares of Kite Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 95 shares during the last quarter.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.